NCT02614911 Characterization of Phenotype and Genotype of Early Onset Enteropathies
| NCT ID | NCT02614911 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imagine Institute |
| Condition | Inflammatory Bowel Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,445 participants |
| Start Date | 2014-06-16 |
| Primary Completion | 2054-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,445 participants in total. It began in 2014-06-16 with a primary completion date of 2054-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study has been set up in order to characterize phenotypes and genotypes of patients with early onset enteropathies. In that goal, Investigators will collect biological samples (mainly blood) of patients suffering from early onset enteropathies and their healthy relatives.
Eligibility Criteria
Main Inclusion Criteria: * Severe chronic enteropathy * Patients developing their first symptoms within the first 6 years of life and, in priority within the first two years of life, or patients with a disease of later onset, in case of a familial history suggestive of inherited mutations notably in families comprising several affected members * OR : Be a patient's relative, even if presenting with enteropathy of later onset. Main Exclusion Criteria: * Subject having participated to any therapeutical clinical study in the 30 days preceding the inclusion in this study,
Contact & Investigator
Frank Ruemmele
PRINCIPAL INVESTIGATOR
Necker - Enfants Malades Hospital
Frequently Asked Questions
Who can join the NCT02614911 clinical trial?
This trial is open to participants of all sexes, studying Inflammatory Bowel Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02614911 currently recruiting?
Yes, NCT02614911 is actively recruiting participants. Contact the research team at nadine.cerf-bensussan@inserm.fr for enrollment information.
Where is the NCT02614911 trial being conducted?
This trial is being conducted at Bordeaux, France, Bron, France, Lille, France, Marseille, France and 8 additional locations.
Who is sponsoring the NCT02614911 clinical trial?
NCT02614911 is sponsored by Imagine Institute. The principal investigator is Frank Ruemmele at Necker - Enfants Malades Hospital. The trial plans to enroll 1,445 participants.